Technology

For 2QFY2016, Lupin posted a poor set of numbers, with the OPM coming in
lower than expected, and consequently the net profit as well. The company
posted a 2.0% growth in sales to Rs3,178cr V/s Rs3,272cr estimated, mainly driven
by the European markets. On the operating front, the Gross margin came in at
64.5% V/s 65.7% expected. Further, a 19.4% yoy and 36.2% yoy rise in the Staff
cost and R&D expenditure led the OPM to come in at 16.6% V/s 24.6% expected
and V/s 24.9% in 2QFY2015. Thus, the net profit came in at Rs408.5cr V/s
Rs578.6cr expected and V/s Rs630.0cr in 2QFY2015, a yoy dip of 35.1%. We
maintain our Neutral stance on the stock.
Below expectation numbers: The company posted a 2.0% yoy growth in sales to
Rs3,178cr V/s Rs3,272cr estimated, mainly driven by European markets. Its key
market US (Rs1,155cr), posted a dip of 9.2% yoy, on account of slow pace of
approvals. The company launched 4 products in the US during the period. The
company expects US sales to get normalized by 4QFY2016. Other key markets:
India, Europe, Japan, South Africa and ROW, posted a growth of 9.4%, 32.2%, –
6.5%, -5.6% and 52.9% yoy, respectively. On the operating front, the Gross
margin came in at 64.5% V/s 65.7% expected. Further, a 19.4% and 36.2% rise
in Staff cost and R&D expenditure led the OPM to come in at 16.6% V/s 24.6%
expected and V/s 24.9% in 2QFY2015. Thus, the net profit came in at Rs408.5cr V/s
Rs578.6cr expected and V/s Rs630.0cr in 2QFY2015, a yoy dip of 35.1%.
Outlook and valuation: We expect Lupin to post a CAGR of 14.6% in net sales
to Rs16,561cr and earnings to report a 13.1% CAGR to Rs68.3/share over
FY2015–17E. Currently, the stock is trading at 36.8x and 27.1x its FY2016E
and FY2017E earnings, respectively. We remain Neutral on the stock.

Download Full Report View Full Report in Browser